Showing 4361-4370 of 5557 results for "".
- Aerolase Art of Diversity Conference Continues Growinghttps://practicaldermatology.com/news/aerolase-art-diversity-conference-continues-growing/2468263/Aerolase’s third annual Art of Diversity conference in Jersey City, New Jersey, lived up to its name, with a diverse mix of practitioners and content that led to an engaging educational program. “The whole idea of the Art of Diversity for Skin Health is that there is an eclectic community
- Organon to Acquire VTAMA Maker Dermavanthttps://practicaldermatology.com/news/organon-acquire-vtama-maker-dermavant/2468226/Organon and Dermavant Sciences Ltd. announced that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant company whose product VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults was approv
- Lebrikizumab Gains FDA Approval for ADhttps://practicaldermatology.com/news/lebrikizumab-gains-fda-approval-ad/2468189/The targeted IL-13 inhibitor lebrikizumab was approved by the US Food and Drug Administration for the treatment of adults and children 12 and older who weigh at least 88 lbs with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies
- Cord Blood Biomarkers and TEWL Predict Atopic Dermatitis in Infantshttps://practicaldermatology.com/news/cord-blood-biomarkers-and-tewl-predict-atopic-dermatitis-infants/2468171/A prospective study reports that elevated levels of CCL17 and IL-31 in cord blood, along with increased transepidermal water loss (TEWL) at the anterior cubital fossa, could help identify infants at higher risk of developing atopic dermatitis (AD) within their first year of life. The study
- Tralokinumab Safe for Special Atopic Dermatitis Populationshttps://practicaldermatology.com/news/tralokinumab-found-safe-special-ad-populations/2468141/A recent retrospective study indicated that tralokinumab was linked with significant improvements in atopic dermatitis (AD) in special populations (SPs) such as the elderly and those with significant comorbidities. Researchers investigating the efficacy and safe
- Lebrikizumab Shows Significant Improvement in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-significant-improvement-atopic-dermatitis/2468116/Lebrikizumab monotherapy showed significant improvements in clinical signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis over 16 weeks, according to new research. The analysis of two phase 3 placebo-controlled studies (ADvocate1 and ADvocate2) looked
- CHE Studies Presented at ESCD 2024 Congresshttps://practicaldermatology.com/news/che-studies-presented-escd-2024-congress/2468089/LEO Pharma A/S presented a range of new population-level and physician-reported data on the prevalence, severity, and treatment of moderate-to-severe chronic hand eczema (CHE). The data forms part of an expansive scientific program from LEO Pharma. Eight posters in total will be shared at the Eur
- Report: Global Skin Cancer Treatment Market to Hit $14.5 Billion by 2031https://practicaldermatology.com/news/global-skin-cancer-treatment-market-poised-rapid-growth-expected-hit-145-billion-2031/2468065/A recent report from Allied Analytics said the global skin cancer treatment market is projected to nearly double, reaching $14.5 billion by 2031, driven by an increasing incidence of skin cancer and advancements in treatment options. The $7.2 billion (2021) treatment market, according to t
- Analysis Shows High Incidence of Skin Eruptions with Tebentafusp in Uveal Melanomahttps://practicaldermatology.com/news/high-incidence-skin-eruptions-tebentafusp-uveal-melanoma/2468062/Tebentafusp-associated skin toxicity was prevalent in patients treated for metastatic uveal melanoma, a recent study reported. Study researchers looked at a cohort study of 33 patients treated with tebentafusp and identified skin symptoms in 26 patients (median follow-up of 21.5 months for
- Study Explores Potential of GLP-1 Agonists for Skin Disease Managementhttps://practicaldermatology.com/news/study-explores-potential-glp-1-agonists-skin-disease-management/2468016/Recent research highlights the potential of GLP-1 agonists in managing dermatological conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease, especially in patients with obesity or type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (G